Invesco
TPTX

Invesco’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Invesco’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-54,718
Closed -$4.12M – 4093
2022
Q2 		$4.12M Buy
54,718
+6,991
+15% +$311K ﹤0.01% 2386
2022
Q1 		$1.28M Buy
47,727
+27,214
+133% +$915K ﹤0.01% 2963
2021
Q4 		$978K Sell
20,513
-2,521
-11% -$113K ﹤0.01% 3073
2021
Q3 		$1.53M Buy
23,034
+1,972
+9% +$140K ﹤0.01% 2936
2021
Q2 		$1.64M Sell
21,062
-212,088
-91% -$15.7M ﹤0.01% 2929
2021
Q1 		$22.1M Sell
233,150
-9,570
-4% -$1.14M 0.01% 1470
2020
Q4 		$29.6M Buy
242,720
+227,288
+1,473% +$24.9M 0.01% 1231
2020
Q3 		$1.35M Buy
15,432
+2,076
+16% +$145K ﹤0.01% 2657
2020
Q2 		$863K Sell
13,356
-2,534
-16% -$146K ﹤0.01% 2858
2020
Q1 		$710K Sell
15,890
-3,740
-19% -$199K ﹤0.01% 2891
2019
Q4 		$1.22M Buy
+19,630
New +$934K ﹤0.01% 2896

Invesco's TPTX Position: Q3 2022 in Review

Invesco sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 54,718 shares — an estimated $4.12M sold.

Invesco first reported a position in TPTX in Q4 2019 and held it in 11 quarters. The position peaked at $29.6M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Invesco reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Invesco sold 54,718 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $4.12M.
  • Invesco first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2019 and held it in 11 quarters.
  • Invesco's Turning Point Therapeutics, Inc. Common Stock position peaked at $29.6M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Invesco's 13F filing for Q3 2022, filed 14 Nov 2022.